Author

D. H. Kim

Observed names: D.H. Kim, Dong-Hyeon Kim

Institution: Celltrion (South Korea)

Observed institution: Celltrion (South Korea)

ORCID: 0000-0003-0585-2432

Observed ORCID: 0000-0003-0585-2432

OpenAlex ID: A5030391847

Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn’s Disease: A Systematic Literature Review and Network Meta-Analysis

2026 · Stefan Schreiber, Silvio Danese, et al. · Advances in Therapy · 5

Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn’s Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial

2026 · Stefan Schreiber, Bruce E. Sands, et al. · Advances in Therapy · 2

Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials

2026 · Marla C Dubinsky, Stefan Schreiber, et al. · Inflammatory Bowel Diseases · 1

Pharmacokinetics and efficacy of subcutaneous infliximab 120 mg every 2 weeks: a post hoc comparison with intravenous dosing in a phase 1 study in patients with inflammatory bowel disease.

2026 · Stefan Schreiber, Byong Duk Ye, et al. · PubMed Central

Ab0344 Efficacy of Subcutaneous Infliximab (ct-p13 Sc) Compared With Intravenous Infliximab in Rheumatoid Arthritis: a Post-hoc Analysis of a Phase 3 Randomized Controlled Trial

2022 · A. Constantin, R. Caporali, et al. · Annals of the Rheumatic Diseases

Works count: 5

Citation count: 8

H-index: 2

I10-index: